The Danaher Corporation is a globally diversified conglomerate that operates in four segments: environmental & applied solutions, life sciences, diagnostics, and dental.

Medical Devices

Danaher

William H. King IV is currently the SVP of Strategic Development at [Danaher](/org/danaher). William has been with [Danaher](/org/danaher) for over 20 years and has held various positions within the company. William started their career at [Danaher](/org/danaher) as a Business Development Manager for the Instrument and Control Group. William was responsible for developing and assessing strategies and M&A opportunities for a $500MM group of engineered products. William was successful in acquiring 4 industrial automation companies for the parent company, creating a new motion control group.

In January 1991, William began working for Perdue Farms as a Logistics Manager. William was responsible for optimizing perishable logistics scheduling for core $1B northeast markets. William was successful in their role and after 5 years with the company, they returned to [Danaher](/org/danaher) Corporation.

William H. King, IV attended Walt Whitman High School before completing a BS in Agriculture and Resource Economics from the [University of Maryland](/org/university-of-maryland). William then went on to earn their MBA from [Harvard Business School](/org/harvard-business-school).

Their manager is Rainer M. Blair, President & CEO. Some of their coworkers include Sangeeta N. Bhatia - Scientific Advisor, Brian Ellis - SVP, General Counsel, and Matt McGrew - EVP, CFO.

William H. King, IV

Feroz Dewan is a Director at [Danaher](/org/danaher). Prior to joining [Danaher](/org/danaher), they were the Head of Public Equities and Partner at [Tiger Global Management](/org/tiger-global-management) from January 2003 to December 2015. From January 2002 to December 2003, they were an Investor at [Silver Lake](/org/silver-lake). From January 1999 to December 2002, they were a Manager at [McKinsey & Company](/org/mckinsey-company).

Feroz Dewan's educational career began at [Princeton University](/org/princeton), where they studied engineering and mathematics. Feroz then attended the [International School Manila](/org/international-school-manila) before transferring to the United World College of South East Asia.

Feroz Dewan

David R. Walt, Ph.D. is the Hansjörg Wyss Professor of Bioinspired Engineering at Harvard Medical School and Professor of Pathology at Harvard Medical School and Brigham and Women’s Hospital, is a Core Faculty Member of the Wyss Institute at [Harvard University](/org/harvard) and is a [Howard Hughes Medical Institute](/org/howard-hughes-medical-institute) Professor. Previously, he was University Professor at [Tufts University](/org/tufts-university). His laboratory pioneered the development of microwell arrays, which revolutionized the field of genetic analysis. Dr. Walt’s laboratory also introduced the idea of digital protein detection by developing a high throughput technology for performing single molecule analysis.  Dr. Walt’s research is aimed at applying new technologies to address unmet clinical diagnostics needs. 

Dr. Walt is the Scientific Founder of Illumina Inc., Quanterix Corp., and has co-founded several other life sciences startups including Ultivue, Inc., [Arbor Biotechnologies](/org/arbor-biotechnologies),  [Sherlock Biosciences](/org/sherlock-biosciences), and Vizgen, Inc. He has received numerous national and international awards and honors for his fundamental and applied work in the field of optical microwell arrays and single molecules. He is a member of the National Academy of Engineering, the National Academy of Medicine, a Fellow of the American Academy of Arts and Sciences, a Fellow of the American Institute for Medical and Biological Engineering, a Fellow of the [National Academy of Inventors](/org/national-academy-of-inventors), and is inducted in the US National Inventors Hall of Fame.

David R. Walt

Angela M. Caliendo, M.D., Ph.D. is the Warren Alpert Foundation Professor of Medicine and Executive Vice Chair of the Department of Medicine at the Warren Alpert Medical School of [Brown University](/org/brown-university).  Dr. Caliendo received a Ph.D. (Biochemistry) and M.D. from Case Western Reserve University School of Medicine and completed an internship and residency in Internal Medicine at Brigham and Women’s Hospital in Boston, MA and an Infectious Diseases fellowship at Massachusetts General Hospital, Boston MA.

Dr. Caliendo’s research has focused on the development of molecular diagnostic tests for the detection and quantification of infectious diseases and assessment of their clinical utility; molecular testing in transplantation; standardization of viral load testing; and evaluation of HIV-1 RNA burden and the development of antiretroviral resistance in HIV-1 seropositive women.

Dr. Caliendo is an Editor for the Journal of Clinical Microbiology, Secretary for the Infectious Diseases Society of America, a Fellow of the Infectious Diseases Society of America and the American Academy of Microbiology.  Dr. Caliendo has published over 160 peer-reviewed manuscripts covering various topics in clinical and diagnostic virology and microbiology.
 

Angela M. Caliendo

Phillip A. Sharp is an Institute Professor at the Massachusetts Institute of Technology and member of the Department of Biology and the Koch Institute for Integrative Cancer Research. He joined the Center for Cancer Research (now the Koch Institute) in 1974 and served as its director for six years, from 1985 to 1991, before taking over as head of the Department of Biology, a position he held for the next eight years. He was founding director of the McGovern Institute, a position he held from 2000 to 2004. 

His research interests have centered on the molecular biology of gene expression relevant to cancer and the mechanisms of RNA splicing. Dr. Sharp has authored over 430 papers. He is an elected member of the [National Academy of Sciences](/org/national-academy-of-sciences), the National Academy of Medicine, the American Academy of Arts and Sciences, the American Philosophical Society, and the Royal Society, UK. Among his many awards are the Nobel Prize in physiology or Medicine, Gairdner Foundation International Award, the Lasker Basic Medical Research Award, and the National Medal of Science. His long list of service includes the presidency of the [AAAS](/org/american-association-for-the-advancement-of-science) (2013) and Chair of the Scientific Advisory Committee of the SU2C Project, AACR. 

A native of Kentucky, Dr. Sharp earned a BA degree from [Union College](/org/union-college), Barbourville, KY, and a Ph.D. in chemistry from the University of Illinois, Urbana-Champaign. Dr. Sharp is a co-founder of [Biogen](/org/biogen) (1978) and served as a member of the Board of Directors (1982–2009) and as Chair of the Scientific Advisory Board. He is also a co-founder of Alnylam Pharmaceuticals Inc. (2002) and continues to serve as a member of the Board of Directors and Chair of the Scientific Advisory Board. Dr. Sharp consults and serves on boards of other biotechnology companies.

Phillip A. Sharp

Rob Hershberg, M.D., Ph.D. is a Venture Partner on the Frazier Life Sciences team with over 25 years of experience as a physician, scientist, and entrepreneur.

Rob joined [Frazier Healthcare Partners](/org/frazier-healthcare-partners)' Life Sciences team as a Senior Advisor in 2015 and rejoined the team as a Venture Partner in 2020.

Rob has been working with Frazier and its portfolio companies as an Entrepreneur-in-Residence, Senior Advisor, and executive for 14 years. He was formerly President and Chief Executive Officer of [VentiRx Pharmaceuticals](/org/ventirx-pharmaceuticals), a Frazier-founded company developing a small molecule therapeutic to activate the immune system against solid tumors. Rob co-founded VentiRx while at Frazier and led the company through its transformational partnership with Celgene. He joined Celgene in 2014 to lead their efforts in Immuno-Oncology, was promoted to Executive Vice President and Chief Scientific Officer in 2016, and was subsequently Executive Vice President and Head of Business Development & Global Alliances and served as a member of the Executive Committee until the acquisition of Celgene by Bristol- Myers Squibb in 2019.

Prior to VentiRx, Rob served as Senior Vice President and Chief Medical Officer of Dendreon Corporation and led clinical development of Provenge, which was approved for metastatic prostate cancer. Before Dendreon, he was Vice President of Medical Genetics at Corixa, a Frazier portfolio company which was acquired by GlaxoSmithKline. Earlier, Rob was an Assistant Professor at Harvard Medical School and an Associate Physician at Brigham and Women’s Hospital in Boston, MA.

Rob completed his undergraduate and medical degrees at the University of California, Los
Angeles and received his Ph.D. at the Salk Institute for Biological Studies.

Robert Hershberg

James J. Collins is the Termeer Professor of Medical Engineering & Science and Professor of Biological Engineering at MIT, as well as a Member of the Harvard-MIT Health Sciences & Technology Faculty. He is also a Core Founding Faculty member of the Wyss Institute for Biologically Inspired Engineering at [Harvard University](/org/harvard), and an Institute Member of the [Broad Institute](/org/broad-institute) of MIT and Harvard.  He is one of the founders of the field of synthetic biology, and his research group is currently focused on using synthetic biology to create next-generation diagnostics and therapeutics. 

The Collins research group works in synthetic biology and systems biology, with a particular focus on using network biology approaches to study antibiotic action, bacterial defense mechanisms, and the emergence of resistance.

Professor Collins' patented technologies have been licensed by over 25 biotech, pharma and medical devices companies, and he has helped to launch a number of companies, including [Synlogic](/org/synlogic) and [Sherlock Biosciences](/org/sherlock-biosciences).  He has received numerous awards and honors, including a Rhodes Scholarship and a MacArthur "Genius" Award, and he is an elected member of the [National Academy of Sciences](/org/national-academy-of-sciences), the National Academy of Engineering, and the National Academy of Medicine.

James J. Collins

Professor Stevens has served as Provost Professor of Biological Sciences and Chemistry, and Director of The Bridge Institute, at the [University of Southern California](/org/university-of-southern-california), a private research university, since July 2014. From 1999 until July 2014, he served as Professor of Molecular Biology and Chemistry with The Scripps Research Institute, a non-profit research organization. Professor Stevens is also Founding Director of the iHuman Institute at ShanghaiTech University, and has launched multiple biotechnology companies focused on drug discovery. 

Professor Stevens is considered among the world’s most influential biomedical scientists in molecular research. A pioneer in human cellular behavior research, he has been involved in the creation of therapeutic molecules that led to breakthrough drugs aimed at curing influenza, childhood diseases, neuromuscular disorders and diabetes. Professor Stevens’ insights in the area of molecular research, as well as his experience bringing industry and academia together to advance drug development, are highly beneficial to [Danaher](/org/danaher) given our strategic focus on the development of research tools used to understand the causes of disease, identify new therapies and test new drugs and vaccines.

Raymond C. Stevens

Ms. List-Stoll has served as Executive Vice President and Chief Financial Officer of Gap Inc., a global clothing retailer, since January 2017. Prior to joining Gap, she served as Executive Vice President and Chief Financial Officer of Dick’s Sporting Goods, Inc., a sporting goods retailer, from August 2015 to August 2016, and with Kraft Foods Group, Inc., a food and beverage company, as Advisor from March 2015 to May 2015, as Executive Vice President and Chief Financial Officer from December 2013 to February 2015 and as Senior Vice President of Finance from September 2013 to December 2013. From 1994 to September 2013, Ms. ListStoll served in a series of progressively more responsible positions in the accounting and finance organization of The [Procter & Gamble](/org/procter-gamble) Company, a consumer goods company, most recently as Senior Vice President and Treasurer. Prior to joining [Procter & Gamble](/org/procter-gamble), Ms. List-Stoll was employed by the accounting firm of Deloitte & Touche for almost ten years. Ms. List-Stoll is a member of the board of directors of Microsoft Corporation.

Ms. List-Stoll’s experience dealing with complex finance and accounting matters for Gap, Dick’s, Kraft and [Procter & Gamble](/org/procter-gamble) have given her an appreciation for and understanding of the similarly complex finance and accounting matters that [Danaher](/org/danaher) faces. In addition, through her leadership roles with large, global companies she has insight into the business practices that are critical to the success of a large, growing public company such as [Danaher](/org/danaher).

Teri List

Ms. Hefner Filler has served as President of Retail Products and Chief Merchandising Officer of Walgreen Co., a national drugstore chain, since January 2015. From March 2013 until June 2014, Ms. Hefner Filler served as President, North America of Claire’s Stores, Inc., a specialty retailer; from May 2007 to June 2012, as Executive Vice President of Wal-Mart Stores Inc., an operator of retail stores and warehouse clubs, and from April 2009 to June 2012 also as Chief Merchandising Officer for Sam’s Club, a division of Wal-Mart; and from May 2004 through December 2006, as Executive Vice President—Global Strategy for Kraft Foods Inc., a food and beverage company.

Ms. Hefner Filler has served in senior management roles with leading retail and consumer goods companies, with general management responsibilities and responsibilities in the areas of marketing, branding and merchandising. Understanding and responding to the needs of our customers is fundamental to [Danaher](/org/danaher)’s business strategy, and Ms. Hefner Filler’s keen marketing and branding insights have been a valuable resource to [Danaher](/org/danaher)’s Board. Her prior leadership experiences with large public companies have given her valuable perspective for matters of global portfolio strategy and capital allocation as well as global business practices.

Linda Hefner Filler

Jose-Carlos (“JC”) is Senior Vice President and Chief Scientific Officer of [Danaher](/org/danaher). In this role, JC is responsible for setting [Danaher](/org/danaher)’s science and technology strategy, supporting M&A and open innovation, and counseling [Danaher](/org/danaher)’s operating companies on innovation opportunities. He leads the [Danaher](/org/danaher) Innovation Centers and the [Danaher](/org/danaher) Scientific Advisory Board. Working with technical leaders across [Danaher](/org/danaher), JC enables innovation best practice sharing and culture building.

JC has diverse leadership experience across multiple biotech start-ups and pharmaceutical companies and deep expertise in translating new areas of science and technology into successful drug discovery and development programs and marketed drugs. Prior to [Danaher](/org/danaher), JC served as Global Head of Drug Discovery at [AbbVie](/org/abbvie), Group SVP Biotherapeutics R&D at [Pfizer](/org/pfizer) and SVP and CEDD Head of Inmuno Inflammation at GlaxoSmithKline. JC was the founding CEO and President at Repertoire Immune Medicine where he built and led a team to decode the human immunome. Previously, he was President and CEO of [Synlogic](/org/synlogic), where he led the company from early discovery to the clinical stage and to the public markets. In these global positions, he oversaw multiple drug discovery teams, resulting in five marketed drugs.

JC has a Ph.D. in immunology from the Universidad Autonoma de Madrid and trained as an immunologist in Spain, Germany and Switzerland. He started his academic career as Assistant Professor of Genetics at Harvard Medical School. He has authored more than 150 peer-reviewed publications.

Jose-Carlos Gutierrez-Ramos

Mr. Sanders is currently Senior Vice President of Business Transformation at [Verizon](/org/verizon-communications) Communications Inc. (NYSE: VZ). Since joining [Verizon](/org/verizon-communications) in 1997, he has served in a series of progressively more responsible leadership positions including as Senior Vice President of Corporate Finance from 2015 to 2020. Prior to joining [Verizon](/org/verizon-communications), Mr. Sanders served in various finance roles at Hallmark Cards, Inc. and Safelite Glass Corporation, and began his career at [Grant Thornton](/org/grant-thornton-international) in 1984.

Mr. Sanders earned his B.S. in Accounting from [Oklahoma City University](/org/oklahoma-city-university) and his M.B.A. from [Rockhurst University](/org/rockhurst-university), and he is a Certified Public Accountant.

A. Shane Sanders

alexis zink

Rainer Blair is the President and Chief Executive Officer of [Danaher](/org/danaher) Corporation. Beginning September 2020, Rainer has led [Danaher](/org/danaher)’s $21B global, multi-industry portfolio of businesses. With the help of [Danaher](/org/danaher)’s 67,000 global associates, he is focused on further strengthening [Danaher](/org/danaher)’s position as a leading science and technology company. 

Rainer is a dedicated leader and practitioner of the [Danaher](/org/danaher) Business System, the company’s pre-eminent operating model and cultural foundation.  He is deeply committed to the company’s Core Values and Shared Purpose: Helping Realize Life’s Potential.  He has been a principle architect of [Danaher](/org/danaher)’s associate engagement strategy and Diversity + Inclusion journey. 

Rainer M. Blair

As Executive Vice President of [Danaher](/org/danaher)’s Product Identification and Water Quality businesses, Joakim provides strategic and operational leadership for many of [Danaher](/org/danaher)’s flagship companies. His strong growth and innovation mindset and experience also makes him the ideal leader of [Danaher](/org/danaher) Labs, the company’s innovation hub focused on the Internet of Things (IoT), analytics and cloud technologies.

Joakim Weidemanis

As Senior Vice President, Corporate Development, Daniel Raskas leads mergers and acquisitions in partnership with Bill King and oversees investment activity, including identification, valuation, due diligence, contract strategy and negotiations.

Daniel joined [Danaher](/org/danaher) in 2004, originally serving as Vice President of Corporate Development, and was promoted to his current role in 2010. Throughout his tenure, he has led business development across the company and overseen a number of major acquisitions, including [Beckman Coulter](/org/beckman-coulter-inc) and [Pall](/org/pall).

Daniel Raskas

Brian Ellis is the SVP and General Counsel at [Danaher](/org/danaher). Brian has also previously served as Associate General Counsel at [GE Healthcare](/org/ge-healthcare-limited), VP and Chief Legal Counsel at Medtronic, Inc., and Partner at Altheimer & Gray. Brian began their career as an Associate at Ungaretti & Harris LLP before becoming an AUSA at the U.S. Department of Justice in 1997.

Brian Ellis attended the University of Illinois Urbana-Champaign, where they received their JD in 1991. Brian then went on to attend the University of Illinois College of Law.

They work with Georgeann Couchara - SVP, HR, William H. King, IV - SVP, Strategic Development, and Jennifer L. Honeycutt - EVP. Brian Ellis reports to Rainer M. Blair, President & CEO.

Brian Ellis

Georgeann Couchara

Leon Williams

Joseph C. DeVille

Sangeeta N. Bhatia MD, PhD is an inventor, Massachusetts Institute of Technology professor and biotech entrepreneur who adapts technologies developed in the computer industry for medical innovation. At MIT, she is the John J. and Dorothy Wilson Professor of Engineering, Director of the Marble Center for Cancer Nanomedicine at the Koch Institute for Integrative Cancer Research, and Investigator of the Howard Hughes Medical Institute. Trained as both a physician and engineer, Sangeeta’s laboratory leverages miniaturization tools from the computer industry for medical innovation with applications in liver disease, cancer and infectious diseases. She and her over 150 trainees have contributed to more than 50 issued or pending patents, launched multiple biotechnology companies to improve human health, and published more than 200 peer-reviewed papers.

Bhatia was the 25th person in history to be an elected member of all three US National Academies: NAS, NAM, and NAE. She has been honored with the Lemelson-MIT Prize (known as the “Oscar” for inventors), the Heinz Medal, and the Othmer Gold Medal for groundbreaking inventions and advocacy for women in STEM fields. She has presented her vision for the application of engineering solutions to solve medical problems on international stages such as the World Economic Forum, TED, the Gates Grand Challenges, and the Biden Cancer Moonshot. She currently serves as a Trustee at Brown University and Director at Vertex Pharmaceuticals.

Sangeeta N. Bhatia

Carl H. June is the Richard W. Vague Professor in Immunotherapy ,Director of the Center for Cellular Immunotherapies and Director of the Parker Institute for Cancer Immunotherapy in the Perelman School of Medicine at the University of Pennsylvania.  He maintains a research laboratory that studies various mechanisms of lymphocyte activation that relate to immune tolerance and adoptive immunotherapy for cancer and chronic infection. In 2011, his research team published findings detailing a new therapy in which patients with refractory and relapsed chronic lymphocytic leukemia were treated with genetically engineered versions of their own T cells. The June laboratory has been highly productive with >500 publications, and a google scholar h-index of 161 with >104,000 citations.

The impact of this work has become widely recognized as a major turning point that is delivering on the long-held promise of cancer gene therapy. The CAR T cells invented in the June laboratory were awarded “Breakthrough Therapy” status by the FDA for acute leukemia in children and adults in 2014 and for adults with lymphoma in 2018. The CAR T cells invented in the June laboratory were approved by the FDA for acute leukemia in 2017 and afterwards, for diffuse large B cell lymphoma. These accomplishments have been recognized by the White House on several occasions.

June has published more than 500 manuscripts and is the recipient of numerous prizes and honors, including election to the Institute of Medicine, the National Academy of Sciences, the American Academy of Arts and Sciences and the American Philosophical Society. He has been awared the Paul Ehrlich and Ludwig Darmstaedter Prize (shared w J. Allison), the Novartis Prize in Immunology (shared w Z. Eshhar and S. Rosenberg), the Karl Landsteiner Memorial award, the Karnofsky Prize from the American Society of Clinical Oncology, the Albany Medical Prize, a lifetime achievement award from the Leukemia and Lymphoma Society, The Lorraine Cross Sanford Health Award for life-changing breakthroughs and innovations in medical science and The Dan David Prize.

Carl H. June

Gwen Gioia

Matt McGrew is the current Executive Vice President and Chief Financial Officer at [Danaher](/org/danaher) Corporation. Prior to joining [Danaher](/org/danaher), Matt spent 10 years at [KPMG](/org/kpmg) in various roles, most recently as Director of Transaction Services.

Matt McGrew has a Bachelor's degree in Accounting from [DePaul University](/org/depaul-university).

They work with Jose-Carlos Gutierrez-Ramos - SVP, Chief Scientific Officer, Brian Ellis - SVP, General Counsel, and Georgeann Couchara - SVP, HR. Matt McGrew reports to Rainer M. Blair, President & CEO.

Matt McGrew

David Rimm is a Professor in the Department of Pathology at the Yale University School of Medicine. He completed an M.D.-Ph.D. at [Johns Hopkins University](/org/johns-hopkins-university) Medical School followed by a Pathology Residency at Yale and a Cytopathology Fellowship at the Medical College of Virginia. He is board certified in Anatomic Pathology and Cytopathology. At Yale since 1994, Dr. Rimm is the Director of Yale Pathology Tissue Services. He is a member of the Executive Team in Pathology and serves as the Director of Translational Pathology. 

His lab group focuses on quantitative pathology using the AQUA® technology invented in his lab with projects related to predicting response to therapy or recurrence or metastasis in breast and lung cancer and melanoma. The technology has also been used in a series of efforts related to biospecimen science. He is also beginning efforts on new high-plex technologies, including Imaging Mass Cytometry and Digital Spatial Profiling. The work is supported by grants from the NIH, BCRF, and sponsored research agreements from biotech and pharma. 

He is a member of a number of correlative science committees for multi-institutional breast cancer clinical trials including SWOG, ALLTO, and TEACH. He also serves on the Molecular Oncology committee for the College of American Pathologists (CAP). He is an author of over 380 peer-reviewed papers and 8 patents. He has served on advisory boards for [Amgen](/org/amgen), Lilly, [Novartis](/org/novartis), Astra Zeneca, BMS, Cepeid, Perkin Elmer, Dako, Ventana, PAIGE.AI and Cell Signaling Technology. He was a scientific co-founder of HistoRx, a digital pathology company (sold to Genoptix in 2012) and Metamark Genetics, a prognostic determinant company.

David Rimm

Jennifer L. Honeycutt is responsible for the Company's Beckman Coulter Life Sciences, [Integrated DNA Technologies](/org/integrated-dna-technologies) (IDT), [Leica Microsystems](/org/leica-microsystems-gmbh), [Molecular Devices](/org/molecular-devices), [Pall](/org/pall), Phenomenex, and [SCIEX](/org/sciex) businesses. With this appointment, Ms. Honeycutt will become an executive officer of the Company.

Prior to this appointment, Ms. Honeycutt, 51 years old, was a Vice President and Group Executive overseeing [Pall](/org/pall), IDT, and the Danaher Life Sciences platform in China, and served as President of [Pall](/org/pall). She previously served as President of Beckman Coulter Life Sciences from 2013 to 2016 and is also a longstanding member of Danaher's Diversity + Inclusion Council.

Jennifer L. Honeycutt

Dr. Mega is currently Chief Medical and Scientific Officer of Verily Life Sciences LLC, an Alphabet, Inc. company, where she has served since March 2015. Prior to joining Verily, she served as Cardiologist and Senior Investigator at Brigham & Women's. Dr. Mega has also served as a faculty member at Harvard Medical School and a senior investigator with the TIMI Study Group, where she helped lead international trials evaluating novel cardiovascular therapies and directed the genetics program.  

Dr. Mega is a graduate of [Stanford University](/org/stanford), Yale University School of Medicine and Harvard School of Public Health. She completed her Internal Medicine Residency at Brigham and Women's Hospital and Cardiovascular Fellowship at Massachusetts General Hospital. She is board certified in Internal Medicine and Cardiology and has won the Laennec Society, Samuel A. Levine, and Douglas P. Zipes Awards. Dr. Mega is also a Fellow of the American Heart Association (AHA) and the [American College of Cardiology](/org/american-college-of-cardiology) (ACC).

Jessica L. Mega

Mr. Rales is a co-founder of [Danaher](/org/danaher) and has served as Chairman of the Executive Committee of [Danaher](/org/danaher) since 1984. He was also President of the Company from 1984 to 1990. Mr. Rales is also a member of the board of directors of each of Colfax Corporation and Fortive Corporation, and is a brother of Steven M. Rales.

The strategic vision and leadership of Mr. Rales and his brother, Steven Rales, helped create the [Danaher](/org/danaher) Business System and have guided [Danaher](/org/danaher) down a path of consistent, profitable growth that continues today. In addition, as a result of his substantial ownership stake in [Danaher](/org/danaher), he is well-positioned to understand, articulate and advocate for the rights and interests of the Company’s shareholders.

Mitchell Rales

From 2000-2018, Mr. Spoon served as Partner Emeritus, General Partner and from 2000-2010, Managing General Partner of [Polaris Partners](/org/polaris-partners), a venture capital company that invests in information technology and life sciences firms.  Mr. Spoon is also a member of the board of Fortive Corporation, IAC/InterActiveCorp., Match Group, Inc. and Cable One, Inc.

In addition to his leadership role at [Polaris Partners](/org/polaris-partners), Mr. Spoon previously served as president, chief operating officer and chief financial officer of one of the country’s largest, publicly-traded education and media companies, and has served on the boards of numerous public and private companies. His public company leadership experience gives him insight into business strategy, leadership and executive compensation and his public company and private equity experience give him insight into technology and life science trends, acquisition strategy and financing, each of which represents an area of key strategic opportunity for the Company.

Alan G. Spoon

Mr. Lohr was a partner of [Hogan Lovells](/org/hogan-lovells), a global law firm, for over five years until retiring in June 2012 and has also served on the boards of private and non-profit organizations.

Prior to his tenure at [Hogan Lovells](/org/hogan-lovells), Mr. Lohr served as assistant attorney general for the State of Maryland. He has extensive experience advising companies in a broad range of transactional matters, including mergers and acquisitions, contests for corporate control and securities offerings. His extensive knowledge of the legal strategies, issues and dynamics that pertain to mergers and acquisitions and capital raising has been a critical resource for [Danaher](/org/danaher) given the importance of its acquisition program.

Walter G. Lohr

Mr. Rales is a co-founder of [Danaher](/org/danaher) and has served as [Danaher](/org/danaher)’s Chairman of the Board since 1984. He was also CEO of the Company from 1984 to 1990. Mr. Rales is also a member of the board of directors of Fortive Corporation, and is a brother of Mitchell P. Rales.

The strategic vision and leadership of Mr. Rales and his brother, Mitchell Rales, helped create the [Danaher](/org/danaher) Business System and have guided [Danaher](/org/danaher) down a path of consistent, profitable growth that continues today. In addition, as a result of his substantial ownership stake in [Danaher](/org/danaher), he is well-positioned to understand, articulate and advocate for the rights and interests of the Company’s shareholders.

Steven Rales

Mr. Schwieters has served as Principal of Perseus Realty, LLC, a real estate investment and development firm, since July 2013. He also served as a Senior Executive of Perseus, LLC, a merchant bank and private equity fund management company, from May 2012 to June 2016 and as Senior Advisor from March 2009 to May 2012. Within the past five years Mr. Schwieters has served as a director of Smithfield Foods, Inc. and Choice Hotels International, Inc.

In addition to his roles with Perseus, Mr. Schwieters led the Mid-Atlantic region of one of the world’s largest accounting firms after previously leading that firm’s tax practice in the Mid-Atlantic region, and has served on the boards and chaired the audit committees of several NYSE-listed public companies. He brings to [Danaher](/org/danaher) extensive knowledge and experience in the areas of public accounting, tax accounting and finance, which are areas of critical importance to [Danaher](/org/danaher) as a large, global and complex public company.

John T. Schwieters

Dr. Zerhouni served as President, Global Research & Development, for [Sanofi](/org/sanofi) S.A., a global pharmaceutical company, from 2011 - 2018. From 2008 until 2011, he provided advisory and consulting services to various nonprofit and other organizations as Chairman and President of Zerhouni Holdings. From 2002 to 2008, Dr. Zerhouni served as director of the [National Institutes of Health](/org/national-institutes-of-health), and from 1996 to 2002, he served as Chair of the Russell H. Morgan Department of Radiology and Radiological Sciences, Vice Dean for Research and Executive Vice Dean of the Johns Hopkins School of Medicine.

Dr. Zerhouni, a physician, scientist and world-renowned leader in radiology research, is widely viewed as one of the leading authorities in the United States on emerging trends and issues in medicine and medical care. These insights, as well as his deep, technical knowledge of the research and clinical applications of medical technologies, are of considerable importance given [Danaher](/org/danaher)’s strategic focus in the medical technologies markets. Dr. Zerhouni’s government experience also gives him a strong understanding of how government agencies work, and his experience growing up in North Africa, together with the global nature of the issues he faced at NIH and his role at France-based [Sanofi](/org/sanofi), give him a global perspective that is valuable to [Danaher](/org/danaher).

Elias A. Zerhouni

Dr. Sabeti is currently an Investigator for [Howard Hughes Medical Institute](/org/howard-hughes-medical-institute), a non-profit medical research organization, where she has served since November 2015.  Dr. Sabeti is a professor at both the Center for Systems Biology and the Department of Organismic and Evolutionary Biology at [Harvard University](/org/harvard) and the Department of Immunology and Infectious Disease at Harvard School of Public Health. She is also a [Broad Institute](/org/broad-institute) Member and a leader in the Broad's Infectious Disease and Microbiome Program.

Dr. Sabeti is a graduate of the Massachusetts Institute of Technology, [University of Oxford](/org/university-of-oxford) (as a Rhodes Scholar) and Harvard Medical School. She is a World Economic Forum Young Global Leader and a National Geographic Emerging Explorer. In 2014, she was named a TIME magazine "Person of the Year" as one of the Ebola fighters and in 2015 as one of TIME's "100 Most Influential People." Her awards include the 2012 Smithsonian American Ingenuity Award for Natural Science, an Ellis Island Medal of Honor, and the 2017 Richard Lounsbery Award from the [National Academy of Sciences](/org/national-academy-of-sciences).

Danaher

About

Photos

Values

Insider experiences

Org chart

Teams

Jobs

Wires

Similar organizations